Ranibizumab-The jury is still out
- PMID: 32627248
- DOI: 10.1111/apa.15256
Ranibizumab-The jury is still out
Comment on
-
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.Lancet. 2019 Oct 26;394(10208):1551-1559. doi: 10.1016/S0140-6736(19)31344-3. Epub 2019 Sep 12. Lancet. 2019. PMID: 31522845 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Zin A, Gole GA. Retinopathy of prematurity - Incidence today. Clin Perinatol. 2013;40:185-200.
-
- Hellstrom A, Smith EH, Dammann O. Retinopathy of prematurity. Lancet. 2013;382:1445-1457.
-
- Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84:77-82.
-
- Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochran Database Syst Rev. 2018;1:CD009734.
-
- Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for Stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603-615.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
